For research and educational purposes only. Not medical advice.
Clomiphene citrate Reference
Educational, not medical advice reference for Clomiphene citrate: Hormonal, Reproductive; regulatory status, evidence posture, source review, and schedule no…
Reference summary
On-label evidence in female ovulation induction is mature. The off-label male hypogonadism use case rests on Moskovic/Katz 2012 BJU Int (long-term safety / effectiveness retrospective in 86 men) and a number of smaller comparative studies vs testosterone replacement. The Endocrine Society 2018 guideline acknowledges the off-label male use but does not recommend it as first-line outside of fertility-preservation contexts.
Regulatory and posture
- Categories
- Hormonal, Reproductive
- Aliases
- Clomid, Serophene, Selective estrogen receptor modulator (racemic mixture of enclomiphene and zuclomiphene isomers; small molecule, not a peptide)
- Evidence posture
- human - Off-label male use is investigational. Vision-related adverse events (blurring, scotomata) are real and require monitoring at higher doses.
- Regulatory status
- FDA-approved as Clomid / Serophene for the treatment of ovulatory dysfunction in women desiring pregnancy. Off-label use for male secondary hypogonadism, HPTA restart after anabolic-steroid exposure, or fertility-preserving alternatives to testosterone replacement is common in andrology and lifting communities but is not an FDA-approved indication. WADA-prohibited at all times under S4.
- Content review status
- label verified